Study Overview: This study is testing a drug called efruxifermin (EFX) for people with compensated cirrhosis due to NASH/MASH. Cirrhosis is when liver tissue gets scarred instead of being healthy. NASH/MASH is a liver problem caused by fat buildup, not alcohol. The study is randomized (participants are randomly chosen to get the drug or not), double-blind (neither the doctors nor the participants know who gets the drug), and placebo-controlled (some people will get a fake treatment, called a placebo, to compare results).
Eligibility: To join, participants should have compensated cirrhosis (liver still works well) caused by NASH/MASH. This could be confirmed by a biopsy (taking a small piece of liver to look at) or other tests. People with other liver diseases, certain types of diabetes, or liver problems that have gotten worse over time can't join.
- Duration & Visits: Participants will need to attend multiple visits over the study period.
- Compensation: Participants may receive compensation for their time and travel expenses.
- Risks: Participants should consider potential side effects or risks associated with the drug or placebo.